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Abstract
There is a daunting challenge to prevent human immunodeficiency virus (HIV) acquisi-
tion in women at high risk of acquiring HIV. Of the 37 million people globally living 
with HIV, more than half are women. Women account for nearly 60% of adults with HIV 
in sub-Saharan Africa, where unprotected heterosexual sex is the primary driver of the 
epidemic. While male condoms are effective, they are not always used, and this is not 
something women can control. Women urgently need prevention tools they can decide 
to use, independent of a husband or partner. Pre-exposure prophylaxis (PrEP), in which 
HIV-uninfected persons with ongoing HIV risk use antiretroviral (ARV) medications as 
chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention 
strategy. We review recent advances in the development of new biomedical HIV preven-
tion interventions with a highlight of findings from pivotal clinical trials, as well as a 
discussion on future generation strategies for women.
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1. Introduction
In 2015, 2.1 million people became newly infected with Human Immuno Deficiency Virus 
(HIV) and 1.1 million died from Acquired Immuno Deficiency Syndrome (AIDS) related 
illnesses [1]. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) 
Global Report, 70 percent of the 37 million people estimated to be living with HIV reside 
in sub-Saharan Africa [1]. In this setting, where unprotected heterosexual sex is the pri-
mary driver of the epidemic, women account for nearly 60 percent of adults with HIV. 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
While existing HIV-1 prevention interventions including behavior change, use of male and 
female condoms, treatment of sexually transmitted infections (STIs), male circumcision, 
and uptake of antiretroviral (ARV) treatment to reduce the infectiousness of persons with 
HIV-1 have gone a long way in controlling the spread of HIV-1 infection [2–6], HIV-1 rates 
in young women in resource limited settings remain unacceptably high [1]. This is in part, 
because many HIV-1 prevention methods require the participation or consent of a male 
partner. Women urgently need prevention tools they can decide to use, independent of a 
husband or partner [7]. Developing HIV prevention options that women can use therefore 
remains a global concern, given the soaring rates of HIV infection among women. Pre-
exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use 
antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a prom-
ising new HIV prevention strategy [8–11].
2. HIV prevention biomedical interventions
2.1. Microbicides
2.1.1. CAPRISA 004
Tenofovir gel was the first ARV-based microbicide to be tested in an effectiveness trial. 
CAPRISA 004 was a phase 2B microbicide study that tested peri-coitally applied 1% TDF 
vaginal gel among 889 South African women conducted from May 2007 to March 2010. 
The trial found a 39% (95% CI, 6–60%; p = 0.017) lower HIV infection rate in women using 
1% tenofovir gel as compared to the women using placebo gel when used in a coitally depen-
dent regimen [12]. Tenofovir gel was shown to be safe when used up to 12 h before sex and 
again within 12 h after sex (BAT), for a maximum of two doses in 24 h. The drug was found 
to be 54% effective among women who were the highest adherers (gel adherence > 80%). 
Participants who adhered to the dosing regimen in more than 80% of sex acts were the least 
likely to acquire HIV (54% lower risk of infection).
2.1.2. FACTS 001
FACTS 001 was a phase III safety and effectiveness double-blind, randomised, placebo-con-
trolled trial of pericoital tenofovir 1% gel for HIV prevention in 18–30 year Women at nine 
sites in South Africa [17]. The study evaluated the safety and effectiveness of pericoital TFV 
1% gel when using the BAT-24 regimen (before and after sex; no more than 2 doses in 24 h) 
among women at nine sites in South Africa. A total of 2059 women were randomized to teno-
fovir 1% gel or to placebo and instructed women to apply the gel 12 h before and within 12 h 
after sex, the same schedule used in CAPRISA 004. The study was conducted between Oct 
2011 and Aug 2014. In 3036 person-years of observation accrued, 123 HIV infections occurred 
(HIV incidence: 4.0/100 women years); 61 in the TFV arm and 62 in the placebo group (inci-
dence rate ratio [IRR], 1.0; 95% CI: 0.7–1.4). In a nested case-cohort sub-study (n = 214) that 
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examined TFV drug levels in quarterly cervicovaginal lavage (CVL) samples in HIV serocon-
verters vs controls, high TFV in CVL was significantly associated with a reduction in HIV 
acquisition (HR, 0.52; 95% CI, 0.27–0.99; p = 0.04).
Considering all adherence data, the FACTS 001 team calculated that women used gel for an 
average of 50–60% of sex acts. Majority of participants were not able to achieve sufficiently 
high levels of gel coverage required for protection which underscores the need for a range of 
HIV prevention options for young women which may be easier to integrate into their lives.
2.2. Oral PrEP
2.2.1. Partner’s PrEP
The Partners PrEP Study was a three-arm phase III, randomized, double-blind, placebo-con-
trolled, 3-arm trial of daily oral TDF & FTC/TDF PrEP for the prevention of HIV acquisi-
tion by HIV seronegative partner in heterosexual HIV serodiscordant partnerships. It was 
one of the two land marker studies that provided evidence to support US Food and Drug 
Administration approval for FTC-TDF PrEP. The study demonstrated PrEP HIV protective 
effectiveness against HIV infection of 67% (95% CI 44–81%, p < 0.0001) for TDF and 75% (95% 
CI 55–87%, p < 0.0001) for FTC/TDF [13] compared to person receiving placebo. The HIV 
protection effects of TDF and FTC/TDF were in women and men. For TDF, efficacy among 
women was 71% and was 63% among men; for FTC/TDF, efficacy was 66% in women and 
84% in men—all were statistically significant. In a follow-on open-label demonstration project 
of integrated delivery of ART and PrEP for prevention in HIV sero-discordant couples, the 
investigators observed virtual elimination of incident HIV [13].
2.2.2. FEM-PrEP Study
The FEM-PrEP Study was a phase 3, randomized, placebo-controlled, trial that assessed of the 
effectiveness of daily oral FTC/TDF for HIV prevention among HIV-uninfected women 18–35 
years in Kenya, South Africa and Tanzania [14]. The trial was stopped early by Independent 
Data Monitoring Committee due to futility at the time of study stop. No significant safety con-
cerns were noted. Adherence by self-report and pill counts was high, but plasma drug levels 
revealed that only 15–26% of samples from seroconverters had TDF detected and only 26–38% 
of non-seroconverting controls. Thus, the investigators concluded that PrEP adherence was 
too low to assess PrEP’s HIV protection. Less than 40% of the HIV-uninfected women in 
the TDF–FTC group had evidence of recent pill use at visits that were matched to the HIV-
infection window for women with seroconversion.
2.2.3. TDF2 study
The TDF2 study was a phase 2B study that assessed the safety, adherence and efficacy of daily 
oral FTC/TDF in 1200 (45.7% women) HIV-uninfected heterosexual male and female partici-
pants aged 18–39 years conducted in Botswana [15]. After a 1563 person-years of observation 
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(median, 1.1 years; maximum, 3.7 years), FTC/TDF PrEP resulted in a 62.6% reduction in HIV 
acquisition for participants assigned to FTC/TDF compared to placebo (HR, 0.37; CI, 21.5–
83.4, p = 0.013). As treated analysis provided protective efficacy of 77.9% (95% CI, 41.2–93.6; 
p = 0.01) for FTC/TDF versus placebo, overall, and 75.4% (23.7, 94.4; p = 0.02) for women. No 
significant safety concerns were noted, though participants randomized to the FTC/TDF arm 
did experience more nausea, vomiting and dizziness than those randomized to placebo.
2.2.4. MTN-003/Vaginal and Oral Interventions to Control the Epidemic (VOICE)
Was a phase 2B safety and effectiveness study of tenofovir 1% gel, tenofovir disoproxil fuma-
rate tablet and emtricitabine/tenofovir disoproxil fumarate tablet for the prevention of HIV 
infection in women [16]. The primary aim of the VOICE trial was to estimate the safety and 
effectiveness of daily treatment with vaginal TFV gel, as compared with placebo gel, and of 
oral TDF and oral TDF-FTC, as compared with oral placebo, in preventing sexually acquired 
HIV-1 infection in women.
A total of 5029 were enrolled in the study were followed up monthly and assessed for HIV sero-
conversion. A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 
per 100 person-years. In the modified intention-to-treat analysis, the effectiveness was −49.0% 
with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97–2.29), −4.4% with 
TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73–1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% 
CI, 0.61–1.21). Adherence to study product among those in the active arms was generally very 
low. TFV was detectable in 30%, 29%, and 25% of random plasma samples from participants 
in the TDF, TDF-FTC, and TFV gel arms of the study, and an inverse correlation was demon-
strable between detection of TFV in plasma and characteristics predictive of HIV-1 acquisition.
2.2.5. Partner’s demonstration project
OLE projects have been called for as part of the pathway to scale-up of PrEP. Previous stud-
ies like the Partner’s PrEP that assessed effectiveness of oral truvada and tenofovir for HIV 
prevention among sero-discordant couples in Kenya and Uganda have shown that when par-
ticipants are given the active product through open-label access projects, even those with 
previous poor adherence during the clinical trial are now more likely to use product when 
they know they are now using the active product [13]. From a protection level of about 73% 
in the partner’s PrEP, researchers have reported substantially reduced HIV risk of up to 95% 
when used with high adherence [17], Figure 1.
2.3. Vaginal rings
2.3.1. MTN-020— A Study to Prevent HIV Infection with a Ring with Extended ring (ASPIRE)
Intravaginal rings offer a strategy to deliver antiretroviral PrEP medications with lesser 
opportunities for adherence challenges than for daily oral pills or vaginal gels [18]. ASPIRE 
was a phase III study conducted among 2629 sexually active HIV-negative women ages 18–45 
at 15 clinical research sites in Malawi, Uganda, South Africa and Zimbabwe to determine 
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whether a vaginal ring containing the ARV drug dapivirine is a safe and effective method 
for protecting against the sexual transmission of HIV when used by women for a month at a 
time. The study found HIV risk was reduced by 27% overall—for women group assigned to 
use the dapivirine ring compared placebo ring group—and 37% in a planned second analysis 
that excluded data from two sites with less than ideal retention and adherence. Notably high 
protection (56%) was observed in women >21 years, who also appeared to use the ring most 
consistently, Figure 2 [10].
Figure 1. HIV incidence in Partner’s PrEP demonstration project [17].
Figure 2. Age and HIV-1 protection in ASPIRE [10].
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A summary of the outcomes of recent HIV prevention trials among women is provided in 
Table 1.
2.3.2. MTN-025—HIV open-label prevention extension (HOPE)
HOPE is an open-label study of vaginal ring for preventing HIV among former ASPIRE par-
ticipants. Women who took part in ASPIRE, a trial that found a vaginal ring containing an 
antiretroviral (ARV) drug called dapivirine was safe and helped protect against HIV, are now 
being offered the opportunity to use the ring as part of a new study called HOPE. HOPE 
builds on the results of ASPIRE by gathering additional information on the ring’s safety, how 
women use the ring knowing that it can help reduce their risk of HIV and the relationship 
between adherence and HIV protection. Women who participated in a similar study called 
the RING study by the international partnership for microbicides (IPM) are being followed up 
under the dapivirine ring extended access and monitoring (DREAM OLE) protocol.
2.4. Discussion
High HIV incidence among young women in Africa [1] highlights the need for female-con-
trolled HIV prevention. Social, structural and economic disparities perpetuate vulnerabilities 
of women. The lower social and economic power of women makes it difficult for them to nego-
tiate safe sex [18]. In stable partnerships, condom use is low, and women are often unaware 
of their partner’s HIV status [19]. Therefore, a need exists for HIV prevention methods that 




Women 889 39% [CI = 6–60] 
effectiveness of coitally-
dependent vaginal TFV gel
iPrEx
Brazil, Ecuador, Peru, South 
Africa, Thailand, US
(Oral Truvada)
Gay men, other MSM, 
transgender women
2499 44% [CI = 15–63] 





Men and women 1200 62% [CI = 22–83] 





Serodiscordant couples 4758 67% [CI = 44–81] efficacy 
daily oral TDF
75% [CI = 55–87] efficacy 
daily oral FTC/TDF
FEM-PrEP
Kenya, S Africa, Tanzania
(Oral Truvada)
Women 1950 Futility of daily oral FTC/
TDF
6% [CI = −52 to 41]
ASPIRE
Uganda, Malawi, South 
Africa, Zimbabwe
Women 2629 27% [CI= 1–46] 
effectiveness of dapivirine 
vaginal ring
Table 1. Outcomes of recent HIV prevention trials involving women.
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women can initiate themselves. Scaling up of proven biomedical technologies for women at 
high risk is therefore a high priority. Daily oral tenofovir-based PrEP, dapivirine vaginal ring 
and antiretroviral treatment as prevention are some of the promising biomedical technologies 
for prevention options for women.
Multiple studies of PrEP have shown that oral ARVs, when used consistently, reduce 
the risk of HIV infection in people who are at high risk by up to 92% including among 
women [5]. Currently, FTC-TDF is the medication with a label indication as PrEP against 
HIV acquisition recommended by the World Health Organization (WHO) and the United 
States Centers of Diseases Control and Prevention [20, 21]. Consequently, recent landmark 
approvals in sub-Saharan Africa, including South Africa [22] and Kenya [23], and commit-
ment from large-scale funding partners (including PEPFAR) are leading to accelerated roll-
out of TDF-based PrEP for high-risk populations. TDF alone or TDF with lamivudine are 
other as an alternative to suggested by WHO [24]. Importantly, other new oral PrEP drugs 
(e.g. maraviroc) are currently being evaluated [25]. Although some PrEP trials in African 
women did not show effectiveness against HIV [14, 16, 26], follow-on analyses from those 
two studies have consistently provided strong evidence of very low adherence to PrEP in 
those studies [16, 27].
Prevention technologies such as vaginal ring containing ARV provide tremendous promise 
for the HIV prevention field as they provide HIV prevention options that fit in women’s lives. 
The recent demonstration of moderate HIV protection conferred by monthly vaginal ring con-
taining medication dapivirine is a step in right direction. An important feature of the dapiv-
irine ring is its high level of safety [28]. This excellent safety profile also suggests that minimal 
medical monitoring would be needed, potentially making it both a practical and cost-effective 
option in under-resourced settings. The next step is to ensure that the vaginal ring is safe for 
all women at risk of HIV acquisition including pregnant and breastfeeding women.
For HIV uninfected women in known serodiscorant partnership, initiation and sustained use 
of ART by their infected male patterns are another highly effective prevention options for 
couples [5]. Women who want to conceive or with HIV positive partners who have not yet 
initiated ART, PrEP as bridge to ART prevention strategy is an attractive and highly effective 
HIV option. In PrEP as a bridge to ART strategy, PrEP is offered to HIV-uninfected person 
as a ‘bridge’ to ART in the discordant partnership—that is, until ART initiation by the HIV-
infected partner and for the first 6 months after ART is started or viral suppression. This 
strategy demonstrated nearly elimination of HIV transmission within serodiscordant couples 
in Uganda and Kenya [29].
A robust pipeline of new PrEP drugs and formulations is not only important for advanc-
ing demonstrated success of products but also for addressing limitations of current bio-
medical technologies with the ultimate goal of prevention options that fit women’s needs 
to ensure they will be used at scale. The current pipeline of ARV-based prevention products 
includes oral pills (miravorac), vaginal rings (tenofovir), vaginal and rectal gels, vaginal 
films, long-acting injectable ARVs (rilpivirine, cabotegravir) and multipurpose technolo-
gies that could combine ARV to reduce women's risk of HIV and STIs while providing 
effective contraception.




Oral PrEP trials have demonstrated a decrease in HIV infection rates of between 44 and 77%. 
But it is now proven that with good adherence, Truvada, a once-a-day pill can reduce HIV 
infection rates by at least 92%. Because of high level of effectiveness, oral PrEP has been 
licensed for high-risk populations in the US, Canada, Kenya and South Africa. Efforts to have 
the dapivirine vaginal ring licensed for HIV prevention among women are currently under-
way. The process is an important one that takes time. It’s anticipated that regulatory approv-
als could be received by 2018 in some countries in Africa. Results of the ASPIRE and RING 
studies are a boost to efforts focused on developing and evaluating next generation products, 
such a 3-month ring (just four rings would provide a woman a full year of protection), and 
combination rings that can provide protection against HIV, other STIs and unintended preg-
nancy. A vaginal ring could offer an important option as part of combination strategies or as a 
stand-alone method for women unable or not willing to use other strategies like medical male 
circumcision, condoms and oral PrEP.
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